Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MALLINCKRODT EXPECTS SALES TO MORE THAN DOUBLE OVER NEXT FIVE YEARS

Executive Summary

MALLINCKRODT EXPECTS SALES TO MORE THAN DOUBLE OVER NEXT FIVE YEARS, to "at least $ 800 mil." by 1994, President C. R. Holman told analysts at a meeting in New York on Nov. 8. Mallinckrodt had sales of $ 343 mil. in 1989. The projected growth "is not just an objective," Holman said, "but a necessity if we are to compete successfully in our chosen markets of radiology, cardiology, nuclear medicine, anesthesiology and critical care." Much of Mallinckrodt's growth strategy turns on the company's line of contrast media products. Specifically, the company is counting on Optiray, its recently introduced nonionic agent, to fuel revenue growth. Optiray will soon be available in a prefilled syringe format, along with Mallinckrodt's other imaging products, the company announced. Beginning in the first quarter of fiscal 1990, Mallinckrodt will offer Ultraject, "the first prefilled plastic syringe for administering x-ray contrast media." Ten years in development, the syringe contains a single dose of contrast media and is designed to reduce dosage error and to protect medical personnel from "cuts, needle sticks and other hazards during material handling." The prefill format was approved by FDA through an NDA on Sept. 29. Among other plans for the next fiscal year, Holman said Mallinckrodt will launch a new renal imaging agent, MAG3, in 1990. A palliative rhenium agent to alleviate the pain of bone cancer is currently in Phase I clinical trials and is expected to enter Phase II in the beginning of 1990.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel